These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 18431037)

  • 1. Pharmacological topics of bone metabolism: the physiological function of the sympathetic nervous system in modulating bone resorption.
    Togari A; Arai M
    J Pharmacol Sci; 2008 Apr; 106(4):542-6. PubMed ID: 18431037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of the sympathetic nervous system in controlling bone metabolism.
    Togari A; Arai M; Kondo A
    Expert Opin Ther Targets; 2005 Oct; 9(5):931-40. PubMed ID: 16185149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sympathetic neural influence on bone metabolism in microgravity (Review).
    Mano T; Nishimura N; Iwase S
    Acta Physiol Hung; 2010 Dec; 97(4):354-61. PubMed ID: 21138811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adrenergic regulation of bone metabolism: possible involvement of sympathetic innervation of osteoblastic and osteoclastic cells.
    Togari A
    Microsc Res Tech; 2002 Jul; 58(2):77-84. PubMed ID: 12203706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are beta-blockers useful in the prevention of osteoporotic fractures?
    Pérez-Castrillón JL; De Luis DA; Duenas-Laita A
    Eur Rev Med Pharmacol Sci; 2009; 13(3):157-62. PubMed ID: 19673165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Control of bone remodeling by nervous system. Regulation of bone metabolism by peripheral nervous system].
    Togari A
    Clin Calcium; 2010 Dec; 20(12):1831-8. PubMed ID: 21123935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose effects of butoxamine, a selective β2-adrenoceptor antagonist, on bone metabolism in spontaneously hypertensive rat.
    Arai M; Sato T; Takeuchi S; Goto S; Togari A
    Eur J Pharmacol; 2013 Feb; 701(1-3):7-13. PubMed ID: 23321373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adrenergic control of bone remodeling and its implications for the treatment of osteoporosis.
    Bonnet N; Pierroz DD; Ferrari SL
    J Musculoskelet Neuronal Interact; 2008; 8(2):94-104. PubMed ID: 18622078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anabolic effects of statin and beta-blocker on bone metabolism].
    Taguchi M; Takeuchi Y
    Clin Calcium; 2004 Dec; 14(12):89-94. PubMed ID: 15577180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of beta-blockers on bone metabolism as potential drugs under investigation for osteoporosis and fracture healing.
    Graham S; Hammond-Jones D; Gamie Z; Polyzois I; Tsiridis E; Tsiridis E
    Expert Opin Investig Drugs; 2008 Sep; 17(9):1281-99. PubMed ID: 18694363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unloading induces osteoblastic cell suppression and osteoclastic cell activation to lead to bone loss via sympathetic nervous system.
    Kondo H; Nifuji A; Takeda S; Ezura Y; Rittling SR; Denhardt DT; Nakashima K; Karsenty G; Noda M
    J Biol Chem; 2005 Aug; 280(34):30192-200. PubMed ID: 15961387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Increased bone resorption by sympathetic nervous activity].
    Togari A
    Clin Calcium; 2006 Feb; 16(2):298-303. PubMed ID: 16465033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Cannabinoids in Bone Metabolism: A New Perspective for Bone Disorders.
    Saponaro F; Ferrisi R; Gado F; Polini B; Saba A; Manera C; Chiellini G
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo.
    Hughes A; Rogers MJ; Idris AI; Crockett JC
    Calcif Tissue Int; 2007 Nov; 81(5):403-13. PubMed ID: 17982704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mechanisms of action of anticatabolic drugs used in osteoporosis therapy].
    Kryśkiewicz E; Lorenc RS
    Endokrynol Pol; 2009; 60(2):134-44. PubMed ID: 19396757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bi-directionally selective bone targeting delivery for anabolic and antiresorptive drugs: a novel combined therapy for osteoporosis?
    Liu J; Zhang H; Dong Y; Jin Y; Hu X; Cai K; Ma J; Wu G
    Med Hypotheses; 2014 Dec; 83(6):694-6. PubMed ID: 25459136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current topics in pharmacological research on bone metabolism: preface.
    Furukawa K; Shinoda H
    J Pharmacol Sci; 2006 Mar; 100(3):187. PubMed ID: 16518077
    [No Abstract]   [Full Text] [Related]  

  • 18. The osteoclast, bone remodelling and treatment of metabolic bone disease.
    Boyce BF; Rosenberg E; de Papp AE; Duong LT
    Eur J Clin Invest; 2012 Dec; 42(12):1332-41. PubMed ID: 22998735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Melatonin and bone status].
    Ostrowska Z; Wołkowska-Pokrywa K; Kos-Kudła B; Swietochowska E; Marek B; Kajdaniuk D
    Pol Merkur Lekarski; 2006 Oct; 21(124):389-93. PubMed ID: 17205785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. β2-Adrenergic signal transduction plays a detrimental role in subchondral bone loss of temporomandibular joint in osteoarthritis.
    Jiao K; Niu LN; Li QH; Ren GT; Zhao CM; Liu YD; Tay FR; Wang MQ
    Sci Rep; 2015 Jul; 5():12593. PubMed ID: 26219508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.